This comprehensive observational cohort study meticulously evaluated the effectiveness and safety associated with the combination therapy of adalimumab and methotrexate in individuals diagnosed with the debilitating condition known as rheumatoid arthritis (RA). The participants in this investigation were systematically categorized into three distinct groups, each receiving different treatment regimens. The findings revealed that the synergistic combination of adalimumab and methotrexate demonstrated a statistically significant superiority over methotrexate used as a standalone treatment in achieving clinically meaningful responses, specifically measured by ACR20, ACR50, and ACR70, during a rigorous nine-month treatment period. In this context,Group IB, which was administered a higher dosage of methotrexate, displayed marginally improved rates of clinical improvement compared to Group IA; however, it is worth noting that the difference between these two groups did not reach statistical significance. As the study progressed to the nine-month mark, an impressive 88.9% of the patients belonging to Group IB successfully achieved an ACR20 response, in stark contrast to the 74.2% of participants in Group IA and the significantly lower 46% observed in the comparison group. Furthermore, analogous trends were noted in the responses corresponding to ACR50 and ACR70, reinforcing the efficacy of the combination therapy. The overall implications of this study strongly suggest that the combination therapy of adalimumab and methotrexate holds a clinically superior position when compared to methotrexate monotherapy in the treatment of rheumatoid arthritis, with the possibility that a higher dose of methotrexate could lead to even more favorable outcomes for patients in need of effective treatment options
This comprehensive observational cohort study meticulously evaluated the effectiveness and safety associated with the combination therapy of adalimumab and methotrexate in individuals diagnosed with the debilitating condition known as rheumatoid arthritis (RA). The participants in this investigation were systematically categorized into three distinct groups, each receiving different treatment regimens. The findings revealed that the synergistic combination of adalimumab and methotrexate demonstrated a statistically significant superiority over methotrexate used as a standalone treatment in achieving clinically meaningful responses, specifically measured by ACR20, ACR50, and ACR70, during a rigorous nine-month treatment period. In this context,Group IB, which was administered a higher dosage of methotrexate, displayed marginally improved rates of clinical improvement compared to Group IA; however, it is worth noting that the difference between these two groups did not reach statistical significance. As the study progressed to the nine-month mark, an impressive 88.9% of the patients belonging to Group IB successfully achieved an ACR20 response, in stark contrast to the 74.2% of participants in Group IA and the significantly lower 46% observed in the comparison group. Furthermore, analogous trends were noted in the responses corresponding to ACR50 and ACR70, reinforcing the efficacy of the combination therapy. The overall implications of this study strongly suggest that the combination therapy of adalimumab and methotrexate holds a clinically superior position when compared to methotrexate monotherapy in the treatment of rheumatoid arthritis, with the possibility that a higher dose of methotrexate could lead to even more favorable outcomes for patients in need of effective treatment options
| № | Муаллифнинг исми | Лавозими | Ташкилот номи |
|---|---|---|---|
| 1 | Toshnazarova N.. | ! | Samarkand State Medical University |
| № | Ҳавола номи |
|---|---|
| 1 | 1.Ibragimov, K. I. (2022a). The risk of cardiovascular disease in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs: A clinic based case control study. Journal of Global Health Reports, 4(2). http://joghr.com/index.php/JGHR/article/view/322.Ibragimov, K. I. (2022b). The risk of cardiovascular disease in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs: A clinic based case control study. Journal of Global Health Reports, 4(2). http://joghr.com/index.php/JGHR/article/view/323.Ibragimov, K., Keane, G., Glaría, C. C., Cheng, J., & Llosa, A. (2019). Haloperidol versus olanzapine for people with schizophrenia. The Cochrane Database of Systematic Reviews, 2019(10), CD013425.4.Ibragimov, K., Keane, G. P., Glaría, C. C.,Cheng, J., & Llosa, A. E. (2024). Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders. Cochrane Database of Systematic Reviews, 7. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013425.pub2/abstract5.Ibragimov, K., Palma, M., Keane, G., Ousley, J., Crowe, M., Carreno, C., Casas, G., Mills, C., & Llosa, A. (2021). Digital mental health care in humanitarian & crisis settings: A mixed-methods exploration during the COVID-19 pandemic. https://europepmc.org/article/ppr/ppr3827326.Ibragimov, K., Palma, M., Keane, G., Ousley, J., Crowe, M., Carreño, C., Casas, G., Mills, C., Llosa, A., M. S. F. Mental Health Working Group, Marques, A., Tijerino, A.-M., Droste, A., Echeverri, C., Fredj, N., Sleit, R., & Sultan, S. F. (2022). Shifting to Tele-Mental Health in humanitarian and crisis settings: An evaluation of Médecins Sans Frontières experience during the COVID-19 pandemic. Conflict and Health, 16(1), 6. https://doi.org/10.1186/s13031-022-00437-17.Ibragimov, K., Perles-Ribes, J. F., & Ramón-Rodríguez, A. B. (2022). The impact of climate change on tourism demand: Evidence from Kazakhstan. Anatolia, 33(2), 293–297. https://doi.org/10.1080/13032917.2022.20295108.Ibragimov, K., Sultonov, I., & Ravshanova,M. (2024). The Effectiveness of the Combination Therapy with biologic DMARDS in Rheumatoid Arthritis. Frontiers of Global Science, 2(1), 17–24.9.Khasan, I., Ibrat, A., Islomovich, S. I., Sukhrobovna, R. M., Islamova, K., & Shuxrat, Z. (n.d.). The Association Between Cardiovascular Disease and Conventional DMARDs in Patients with Rheumatoid Arthritis. International Journal of Health Sciences, 6(S8), 5053–5059.10.Ravshanova, M., Ibragimov, K., Uralov, R., Xasanov, F., Islamova, K., Abdushukurova, K., Sultonov, I., & Axmedov, I. (2024). Clinical and Immunological Characteristics of Patients with Rheumatoid Arthritis on Synthetic DMARDS Therapy. Frontiers of Global Science, 2(1), 41–47.11.Ravshanova, M. S., & Ibragimov, K. I. (2022). EFFECTIVENESS OF TRANSVAGINAL ULTRASOUND IN DIAGNOSIS OF ECTOPIC PREGNANCY. INTERNATIONAL SCIENTIFIC CONFERENCE" INNOVATIVE TRENDS IN SCIENCE, PRACTICE AND EDUCATION, 1(2), 114–115. https://scholar.google.com/scholar?cluster=6826578166019760384&hl=en&oi=scholarr12.Tashinova, L., Khamraeva,N., Mambetova, L., Khasanov, F., & Ibragimov, K. (2023). Risk factors for the development of systemic lupus erythematosus (sle) in asians: A research case-control. BIO Web of Conferences, 65, 05017. https://www.bio-conferences.org/articles/bioconf/abs/2023/10/bioconf_ebwff2023_05017/bioconf_ebwff2023_05017.html |